- Contact Us
- Locations & Directions
- Medical Staff Directory
- Careers
- Giving
- International Patients




Find a Clinical Trial by Phase
- Anus
- Brain and Nervous System
- Breast
- Cervix
- Colon
- Disease-free
- Endometrium
- Esophagus
- Eye and Orbit
- Head & Neck
- Hodgkin's Lymphoma
- Kaposi's sarcoma
- Kidney
- Leukemia
- Liver
- Lung
- Melanoma
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Ovary
- Pancreas
- Prostate
- Rectum
- Sarcoma
- Small Intestine
- Stomach
- Thyroid
- Urinary Bladder
New studies open frequently, please check back for updates
- Brain and Nervous System
- Kidney
- Leukemia
- Melanoma
- Non-Hodgkin's Lymphoma
- Ovary
- Pancreas
- Prostate
- Sarcoma
- Small Intestine
New studies open frequently, please check back for updates
- Amersi, Farin
- Arditi, Moshe
- Asher, Arash
- Ayoub, Walid
- Bae, Hyun
- Balmanoukian, Ani
- Basho, Reva
- Boin, Francesco
- Burch, Miguel
- Burford, Matthew
- Burnison, Michele
- Burwick, Richard
- Cass, Ilana
- Chaux, George
- Chen, Peter
- Chiu, Vi K.
- Chung, Alice
- Chung, Jeffrey
- Danovitch, Itai
- Darrah, Justin
- Daskivich, Timothy
- Esmailian, Fardad
- Faries, Mark
- Figlin, Robert
- Figueiredo, Jane
- Fleshner, Phillip
- Freedland, Stephen
- Friedman, Oren
- Gaddam, Srinivas
- Garcia, Maurice
- Gaultier, Cyril
- Gayther, Simon
- Ghandehari, Sara
- Giuliano, Armando
- Gong, Jun
- Goodarzi, Mark
- Goodman, Marc
- Gresham, Gillian
- Gupta, Amit
- Gutierrez, Rodolfo
- Hage, Antoine
- Hamid, Omid
- Hendifar, Andrew
- Hitchins, Megan
- Ho, Allen
- Hu, Jethro
- Huang, Edmund
- Jordan, Stanley
- Kamil, Elaine
- Kim, Hyung
- Kulber, David
- Labadzhyan, Artak
- Lawrenson, Kate
- Lewis, Richard
- Liu, Gene
- Liu, Quin
- Lo, Simon
- Majlessipour, Fataneh
- Makkar, Rajendra
- Mandelbaum, Bert
- McArthur, Heather
- Mehmi, Inderjit
- Merin, Noah
- Mita, Alain
- Mita, Monica
- Moser, Franklin
- Natale, Ronald
- Noureddin, Mazen
- Osipov, Arsen
- Pandol, Stephen
- Paquette, Ronald
- Paski, Shirley
- Patel, Jignesh
- Posadas, Edwin
- Rader, Florian
- Reckamp, Karen
- Rimel, Bobbie Jo
- Rokhsar, Sepehr
- Rosenbloom, Barry
- Rudnick, Jeremy
- Sandler, Howard
- Sankhala, Kamalesh
- Scher, Kevin
- Scott, Victoria
- Shiao, Stephen
- Sicotte, Nancy
- Stone, Michael
- Sundaram, Vinay
- Syal, Gaurav
- Tagliati, Michele
- Tajbakhsh, Jian
- Tan, Echo
- Tapson, Victor
- Toossi, Shahed
- Wachsman, Ashley
- Wentzel, Kristopher
- Yang, Ju Dong
- Zumsteg, Zachary
The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.
- 5-fluorouracil
- ALKS 4230
- AMG 650
- ASTX295
- AZD-2281
- AZD9291
- Ado-trastuzumab Emtansine
- Adriamycin
- Adrucil
- Afatinib
- Alimta
- Apalutamide
- BA3011
- BAY 1747846
- BNT411
- Blinatumomab
- CART-TnMUC1
- CDX-301
- CPT-11
- CPX-351
- Cabozatinib
- Camptosar
- Capecitabine
- Carboplatin
- Cerubidine
- Cetuximab
- Cyclophosphamide
- Cytarabine
- Cytosar
- Cytoxan
- DKN-01
- DPX-Survivac
- DSP-7888
- Dabrafenib
- Daunorubicin
- Decadron
- Defactinib
- Dexamethasone
- Doxorubicin
- Eloxatin
- Erbitux
- Etoposide
- GC4419
- GSK3359609
- GSK6097608
- Gefitinib
- Gemtuzumab ozogamicin
- Gemzar
- Gilotrif
- Herceptin
- Hiltonol
- IBI322
- IMC-C103C
- INCB106385
- INCMGA00012
- INO-5151
- Ibuprofen
- Inotuzumab Ozogamicin
- Ipilimumab
- Iressa
- Itraconazole
- JNJ-61186372
- JNJ-73841937
- LOAd703
- LTT462
- LXH254
- LY3475070
- Lovaza
- Lumason
- MDX-101
- MEDI1191
- MK-7684
- Mercaptopurine
- Methotrexate
- Motrin
- Mutamycin
- NA
- NC318
- NKTR-214
- NT219
- NanoPac
- Necitumumab
- Neoprofen
- Nivolumab
- Olaparib
- Omega-3 Fatty Acid
- Oncaspar
- Onivyde
- Oxaliplatin
- PT2977
- Paraplatin
- Pegaspargase
- Pembrolizumab
- Pemetrexed
- Platinol
- Prednisone
- Purinethol
- RTX-240
- Rifadin
- Rifampin
- SGN-1-LIV1A
- SQL70
- SQP33
- Savolitinib
- Sporanox
- Sunitinib
- Sutent
- TBX-3400
- Tabloid
- Tazemetostat
- Thioguanine
- Tislelizumab
- Tocilizumab
- Trametinib
- Trastuzumab
- VS-6063
- Vepesid
- Vincristine
- XL-184
- Xeloda
- Yervoy
- alectinib
- atezolizumab
- avasopasem manganese
- bempegaldesleukin
- cisplatin
- clazakizumab
- crizotinib
- dostarlimab
- durvalumab
- enfortumab vedotin
- gadobutrol
- gemcitabine
- irinotecan
- lenvatinib
- leucovorin
- liposomal cytarabine-daunorubicin
- mFOLFIRINOX
- mRNA-4157
- mitomycin
- osimertinib
- poly-ICLC
- ribociclib
- selpercatinib
- seribantumab
- stereotactic body radiation therapy (SBRT)
- tucatinib
- Back to Phases
Phase: II
50 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.
Doctor | Protocol No. | Title |
---|---|---|
Chen, Peter | J2W-MC-PYAB | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants with Mild to Moderate COVID-19 Illness |
Chen, Peter | PLN-74809-ARDS-204 | A randomized, double-blind, dose-ranging, placebo controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19 (INTEGRIS-ARDS) |
Chiu, Vi K. | 226688 | 226688: An Open Label, Multicenter, Safety and Efficacy Phase 2 Study of PRL3-Zumab in Solid Tumors (IRB#933) |
Chiu, Vi K. | DEK-DKK1-P205 | DEK-DKK1-P205: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish) (IRB#782) |
Chung, Alice | IIT2015-06-CHUNG-SNBO | Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 65 (IRB#41396) |
Faries, Mark | MRNA-4157-P201 | MRNA-4157-P201: A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (IRB#57650) |
Figlin, Robert | PT2977-201 | PT2977-201: A Phase 2 Trial of PT2977 In Combination With Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (IRB#54237) |
Freedland, Stephen | IIT2018-06-FREEDLAND-AS3 | IIT2018-06-FREEDLAND-AS3 (CAPS3): Carbohydrate and Prostate Study 3: Carbohydrate restricted diet intervention for men on prostate cancer active surveillance (IRB#53710) |
Freedland, Stephen | IIT2018-23-FREEDLAND-POWR | IIT2018-23-Freedland-POWR: WALNUTS for POWER: Polyphenols, Omega-3 fatty acids, Weight loss, and EneRgy (IRB#55792) |
Gaultier, Cyril | AIC316-03-II-01 | A randomized, open label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised adults (PRIOH-1) |
Gong, Jun | ACCRU-GI-1617-SGNTUC-017 | ACCRU-GI-1617-SGNTUC-017/MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (IRB#492) |
Goodman, Marc | IIT2016-14-GOODMAN-NWUHCC | Statin Therapy to Reduce Disease Progression from Liver Cirrhosis to Cancer (IRB#47043) |
Gupta, Amit | A031701 | A031701: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations, (IRB#839) |
Hamid, Omid | CLXH254C12201 | CLXH254C12201: A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma (IRB#0975) |
Hamid, Omid | CPDR001J2201 | A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (IRB#53431) |
Hamid, Omid | EIIT2020-HAMID-S19-00008 | S19-00008: A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma (IRB #390) |
Hamid, Omid | TAPUR | Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119) |
Hendifar, Andrew | IIT2018-29-HENDIFAR-PNCX3 | IIT2018-29-Hendifar-PNCX3: PANCREATIC-ENZYME REPLACEMENT THERAPY WITH PANCREAZE (PANCRELIPASE) DELAYED-RELEASE IN ADDITION TO STANDARD OF CARE FOR BORDERLINE RESECTABLE, LOCALLY ADVANCED, ADVANCED, AND UNRESECTABLE PANCREATIC ADENOCARCINOMA PATIENTS (PANCAX-3) WITH CACHEXIA AND EXOCRINE PANCREATIC INSUFFICIENCY (IRB#208) |
Hendifar, Andrew | MK-3475-158 | MK-3475-158-00: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) (IRB#43687) |
Hendifar, Andrew | MK-7339-002 | MK7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (IRB#57241) |
Jordan, Stanley | CLAZACOVID19 | A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL-6 monoclonal) compared to placebo for the treatment of COVID-19 infection |
Kulber, David | 2019-SCAR-01 | A Phase 2b/3 Randomized, Prospective, Double-Blind, Within-Subject Vehicle Controlled, Multi-Center Study to Determine the Efficacy and Safety of Granexin® Gel (100 uM and 200 uM concentration) in Reducing Scar Formation in Surgical Wounds following Bilateral Anchor Incision Breast Surgery |
Lo, Simon | NANOPAC-2016-05 | NANOPAC-2016-05: Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma (IRB#49989) |
Majlessipour, Fataneh | APEC1621B | APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations (IRB#57477) |
Majlessipour, Fataneh | APEC1621MASTER-APEC1621SC | APEC1621MASTER-APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master and Screening Protocol (IRB#57413) |
McArthur, Heather | EIIT2020-MCARTHUR-TDM1 | EIIT2020-McArthur-TDM1: A randomized phase II study to evaluate efficacy of T-DM1 with or without Palbociclib in the treatment of patients with metastatic HER2 positive breast cancer (IRB#132) |
McArthur, Heather | IIT2018-01-MCARTHUR-IPI | IIT2018-01-McArthur-IPI: A Single Arm Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer (IRB#52157) |
McArthur, Heather | IIT2018-04-MCARTHUR-NEOHP | IIT2018-04-MCARTHUR-NEOHP: Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab (IRB#53566) |
Mehmi, Inderjit | EA6192 | EA6192: A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) (IRB#1205) |
Mita, Alain | EAY131 | EAY131: Molecular Analysis for Therapy Choice (MATCH) (IRB#41419) |
Mita, Alain | P1719-SUR-Z11 | P1719-SUR-Z11: A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours. (IRB#57155) |
Moser, Franklin | 20241 | 20241: Multicenter, single-blind, adaptive dose finding study of single intravenous injections of BAY 1747846 with corresponding blinded read in adult participants with known or highly suspected CNS lesions referred for contrast-enhanced MRI of the CNS (IRB#430) |
Natale, Ronald | D6186C00001 | D6186C00001:A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD) (IRB#97) |
Noureddin, Mazen | C2541013 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 |
Noureddin, Mazen | VK2809-202 | VK2809 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VK2809 ADMINISTERED FOR 52 WEEKS FOLLOWED BY A 4-WEEK OFF-DRUG PHASE IN SUBJECTS WITH BIOPSY PROVEN NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS |
Rader, Florian | CY6021 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CK3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION |
Reckamp, Karen | ELVCAP-001-01 | ELVCAP-001-01: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (IRB#862) |
Reckamp, Karen | U31402-A-U201 | U31402-A-U201 (HERTHENA-Lung01): A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402)in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (IRB#942) |
Rimel, Bobbie Jo | BBI-DSP7888-102CI | BBI-DSP7888-102CI: A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors (IRB#753) |
Rokhsar, Sepehr | ME-401-003 | ME-401-003: A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies (IRB#509) |
Rudnick, Jeremy | A071701 | A071701: Genomically-Guided Treatment Trial in Brain Metastases (IRB#645) |
Rudnick, Jeremy | NRG-BN007 | NRG-BN007: A Randomized Phase II/III Open-Label Study Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT Unmethlyated Glioblastoma (IRB#1075) |
Sandler, Howard | RTOG-3506 | RTOG-3506: (STEEL) A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features (IRB#220) |
Tapson, Victor | 20-0006 | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults |
Tapson, Victor | MK-4482-001 | A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adultswith COVID-19 |
Wentzel, Kristopher | 8951-CL-0103 | A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression. (IRB#52384) |
Yang, Ju Dong | IIT2020-01-YANG-G1001 | IIT2020-01-YANG-G1001:Case-Control Study of the Glycotest HCC Panel vs AFP for the Detection of Early-Stage Hepatocellular Carcinoma (IRB#399) |
Zumsteg, Zachary | IIT2019-20-ZUMSTEG-HPVOPC | IIT2019-20-ZUMSTEG-HPVOPC: Phase II Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer (IRB#900) |
Zumsteg, Zachary | NRG-HN004 | NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin (IRB#46) |
Zumsteg, Zachary | NRG-HN005 | NRG-HN005: A RANDOMIZED PHASE II/III TRIAL OF DE-INTENSIFIED RADIATION THERAPY FOR PATIENTS WITH EARLY-STAGE, P16-POSITIVE, NON-SMOKING ASSOCIATED OROPHARYNGEAL CANCER (IRB#189) |